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Perspectives
Disease Burden
Cholera is a diarrhoeal disease caused 
by Vibrio cholerae O1 and O139, 
transmitted through the faeco-oral 
route. The disease occurs in outbreaks 
but can establish itself permanently. 
The full impact of the disease is 
difﬁcult to assess. The currently 
preferred measure of disease burden, 
disability-adjusted life years, fails to 
capture the enormous impact of a 
cholera outbreak, which spares no age 
group and paralyses the economy in 
severely affected areas.
The seventh cholera pandemic 
began in Indonesia in 1961 and spread 
quickly to other Asian countries, 
which became the epicentre of 
cholera outbreaks. With the economic 
emergence of Asia the number of 
cholera cases reported from that 
region has decreased. There are 
several possible reasons to explain this 
decline. First, massive investment has 
been made in providing a safe water 
supply and in sanitation. Second, 
reporting of cholera has become 
less reliable, because global trade—
especially trade in seafood—and 
tourism are negatively affected by 
cholera outbreak reports. 
In 1970 Vibrio cholerae O1 El Tor 
invaded sub-Saharan Africa, which had 
not experienced cholera for more than 
100 years. In 2006, Africa reported 
234,349 cases of cholera to the 
World Health Organization (WHO), 
accounting for 99% of the ofﬁcially 
notiﬁed global cholera [1]. Between 
1995 and 2005, 66% of cholera 
outbreak reports to ProMedmail (a 
global electronic reporting system 
for outbreaks of emerging infectious 
diseases and toxins, run by the 
International Society for Infectious 
Diseases, at http://www.promedmail.
org/) came from sub-Saharan Africa 
[2]. There is growing evidence of the 
large and increasing burden of cholera 
in Africa. 
Most recently the US-led invasion 
of Iraq has been accompanied by a re-
emergence of cholera in that country. 
As of September 2007, nearly 7,000 
cholera cases from the Sulaymaniyah 
and Kirkuk Governates have been 
reported to WHO [3]. 
Cholera Control and Vaccines
Cholera was eliminated from the 
industrialized world through safer 
water supplies, better sanitation, and 
improved food hygiene. These have 
been the accepted control mechanisms 
for the disease, but as the emergence 
of cholera in Iraq illustrates, the 
provision of safe water and sanitation 
breaks down during wars and complex 
humanitarian emergencies. In addition 
to these crisis situations, cholera also 
thrives in the ever-increasing slums 
of some megacities such as Kolkata 
(formerly Calcutta), India, which are 
not quickly accessible to improvements 
in infrastructure. 
In 2002, WHO mentioned for 
the ﬁrst time the potential use of 
oral cholera vaccines in endemic 
and epidemic situations [4]. Up 
to that point cholera vaccines 
were recommended for individual 
travellers to endemic countries but 
not for public health use in endemic 
countries. Far from embracing 
vaccinations for cholera control, WHO 
experts recommended gaining more 
experience through demonstration 
projects. Since then, mass oral cholera 
vaccinations have been conducted 
in Beira, Mozambique, in Darfour, 
Sudan, and in Aceh, Indonesia. These 
projects demonstrated the feasibility 
and effectiveness of vaccination under 
actual public health conditions [5]. 
A WHO meeting at the end of 2005 
suggested that “… the use of oral 
cholera vaccines in certain endemic 
situations should be recommended…” 
[6].
The slow acceptance of vaccines for 
cholera control is probably related 
to the poor performance of earlier 
generations of cholera vaccines 
made from phenol-killed whole-cell 
preparations of V. cholerae O1 organisms 
and administered by injection as two 
doses, two weeks apart. The vaccine 
offered about 50% protection for a 
short duration, was associated with 
painful local inﬂammatory reactions, 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Longini IM, Nizam A, Ali M, Yunus M, 
Shenvi N (2007) Controlling endemic 
cholera with oral vaccines. PLoS Med 
4(11): e336. doi:10.1371/journal.
pmed.0040336
Using data from Bangladesh, Ira 
Longini and colleagues develop a 
mathematical model predicting that 
oral vaccination of 50%–70% of the 
population could control cholera 
transmission in an endemic region.
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and is no longer recommended for use 
[7].
Currently two cholera vaccines are 
internationally licensed: (1) Dukoral, 
consisting of inactivated whole cells 
of V. cholerae O1 combined with the 
B-subunit (BS-WC) of the cholera 
toxin, and (2) the live attenuated 
vaccine CVD 103HgR (Orochol or 
Mutacol). Both vaccines have an 
excellent safety proﬁle and afford 
high rates of protection over several 
years. The companies producing 
each vaccine have been acquired 
in the last two years by the publicly 
listed Dutch company Crucell. Only 
Dukoral is currently produced, and 
for this reason was used in the above-
mentioned vaccination campaigns in 
Mozambique, Sudan, and Indonesia. 
Dukoral costs travellers more than 
US$10 per dose, and two doses two 
weeks apart are recommended for 
immunisation. Most tourists can 
afford this vaccine, and well-supported 
foundations can purchase this vaccine 
for interventions in larger populations. 
Yet Dukoral is likely to remain too 
expensive for governments of cholera-
endemic regions to vaccinate at-risk 
populations. The technology on 
which Dukoral is based has previously 
been transferred to manufacturers 
in Vietnam, and has been more 
recently transferred to an Indian 
vaccine producer with certiﬁcation 
to produce internationally licensed 
vaccines. There is therefore a justiﬁed 
hope that this vaccine candidate will 
become available internationally at an 
affordable price.
The ideal cholera vaccine is safe 
and affords extended if not lifelong 
protection after a single dose. It can be 
stored for extended periods at room 
temperature and is in the same price 
range as vaccines included in the WHO 
Expanded Program on Immunization. 
Promising candidates approaching this 
ideal are under development. Peru-
15, for example, is a live, attenuated 
vaccine candidate that has been 
found to be safe and immunogenic 
in infants and children in Bangladesh 
[8,9]. Because cold storage presents 
a challenge for the use of this vaccine 
in tropical cholera endemic regions, 
a thermostable vaccine is under 
development. A promising live, 
attenuated cholera vaccine candidate 
is being developed by the Cuban 
Finley Institute (Camaguey, Cuba); this 
candidate is currently under evaluation 
in sub-Saharan Africa and could 
become available at an affordable price 
[10].
Herd Protection Conferred By Oral 
Cholera Vaccines
With the current availability of one 
vaccine, the development of better 
candidates, and the endorsement of 
WHO, wider use of vaccines for cholera 
control looks promising. From a policy 
maker’s perspective, it would be useful 
to know the level of vaccine coverage 
to aim for to control cholera in a 
community, and second, whether this 
approach is cost-effective. 
Recent evidence for herd 
protection conferred by oral cholera 
vaccinations suggests that immunising 
a fraction of a community reduces the 
transmission of cholera sufﬁciently 
for the unvaccinated members of the 
community to beneﬁt from reduced 
risk of disease [11]. However, while 
it has become clear that oral cholera 
vaccine programs will be more cost-
effective than previous trial data 
had suggested, the level of coverage 
required to control cholera remains 
unknown.
In a study published in this issue 
of PLoS Medicine, Ira Longini and 
colleagues [12] have mathematically 
simulated varying vaccine coverage 
levels in the Matlab region of 
Bangladesh using a historic vaccine 
trial dataset [13,14]. Their simulations 
suggest that in a population in which 
50% received an oral cholera vaccine, 
93% of the overall population would 
be protected; this level of protection, 
the authors think, would result in 
control of cholera transmission. To 
make their model more generalisable, 
they modiﬁed the assumptions in a 
sensitivity analysis. For populations 
that have less natural immunity than 
Matlab, 70% coverage would likely 
be necessary to provide sufﬁcient 
protection to control cholera.
If the authors are correct, an 
achievable goal of 50% vaccine 
coverage could protect high-risk 
populations suffering recurrent cholera 
outbreaks. This suggestion is highly 
encouraging, because 50% vaccine 
coverage has been achieved in earlier 
mass vaccination campaigns. Current 
problems in eradication of poliovirus 
illustrate how difﬁcult it is to reach 
the last 10% of the population to drive 
coverage above 90%. Reaching only 
half of the population is comparatively 
easy.
What Remains to be Done?
The ﬁndings of Longini and colleagues 
are encouraging, but policies tend to 
rely on actual ﬁeld-derived data, not 
on models. The authors had access 
to one dataset from a trial conducted 
more than 20 years ago in the Bay of 
Bengal, a place considered at the time 
by cholera experts as the “home of 
cholera,” probably not representative 
for the global cholera situation in 2007. 
More data from a variety of settings is 
now needed. 
Based on the models provided by 
Longini and colleagues, we would 
expect that mass vaccination campaigns 
with reasonable coverage in isolated 
areas with stable populations should 
eliminate cholera for several years. 
In contrast, vaccination campaigns 
in urban slums with highly mobile 
populations could have a lower impact. 
Nothing is known about the impact 
of a combination of improved water 
supplies and sanitation with vaccination 
campaigns, which could be additive 
or synergistic. The key to a better 
understanding is close documentation 
of interventions and outcomes, which 
will allow us to conﬁrm or reject 
Longini and colleagues’ models. 
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